This article appears in the following NDT Plus issue: Parathyroid Intervention - Current themes and future perspectives [View the issue table of contents]
Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
1 Department of Nephrology, Akebono Clinic, Kumamoto
2 Kidney Center, Toranomon Hospital, Minatoku, Tokyo
3 Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Hyogo, Japan
Correspondence: Motoko Tanaka, Department of Nephrology, Akebono Clinic, 5-1-1, Shirafuji, Kumamoto 861-4112, Japan. Tel: +81-96-358-7211; Fax: +81-96-358-7226; E-mail: tanaka{at}matusita-kai.or.jp
 |
Abstract |
|---|
Purpose. Secondary hyperparathyroidism with nodular hyperplasia is resistant to medical therapies. Cinacalcet is an effective treatment for severe secondary hyperparathyroidism. This multicentre retrospective study was designed to determine the long-term efficacy of cinacalcet in patients with nodular hyperplasia, the advanced type of parathyroid hyperplasia.
Subjects and methods. The study subjects were 20 haemodialysis patients with secondary hyperparathyroidism. Patients with ultrasonographically confirmed large parathyroid glands (volume >0.5 cm3) were considered to have nodular hyperplasia (n = 8). Cinacalcet was started at the dose of 25 mg/day and titrated up to 100 mg/day to achieve the target intact-parathyroid hormone (iPTH) level of <250 pg/ml. Serum iPTH, corrected calcium, serum phosphorus, calcium x phosphorus product were measured and compared over the 48-week period of treatment with cinacalcet in all 20 patients and over 120 weeks in 6 of the patients (2 with nodular hyperplasia and 4 with non-nodular hyperplasia). We also examined the achievement rate of K/DOQI guideline treatment targets. The dosages of vitamin D preparation, sevelamer hydrochloride and calcium- containing phosphate binder were adjusted for the above target values.
Results. iPTH levels were significantly lower at 48 weeks in both groups. However, corrected calcium levels, serum phosphorus levels and calcium phosphorus products were within the target values in the non-nodular hyperplasia group (n = 12), while the target value could not be achieved in the nodular hyperplasia group. In the long-term follow-up group, the levels of iPTH, corrected calcium, serum phosphorus and calcium x phosphorus products were significantly higher in nodular hyperplasia than in non-nodular hyperplasia.
Conclusion. Our study suggests that cinacalcet lacks long-term efficacy in nodular hyperplasia, especially for controlling serum calcium and phosphorus levels.
Key Words: cinacalcet • haemodialysis • nodular hyperplasia • secondary hyperparathyroidism • ultrasonography
Received for publication February 28, 2008. Accepted for publication March 18, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Komaba and M. Fukagawa Regression of parathyroid hyperplasia by calcimimetics--fact or illusion? Nephrol. Dial. Transplant., March 1, 2009; 24(3): 707 - 709. [Full Text] [PDF]
|
|